JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (hereafter abbreviated...
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche...
Gennisium finds a strategic partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonatology. Pierre Fabre strengthens its activities in the field of rare diseases, and more specifically pediatric ones. This partnership paves the way for further collaboration between the two companies and marks a...
FWD Group survey finds people in Asia view mental health as a critical concern, yet are unlikely to seek external support – positive reframing of the issue may hold...
65% of people in Asia believe mental health will be one of the most critical issues in the coming year, yet only one-third are open to seeking external support 31% of respondents in Asia believe renaming "mental health" can help people to open up 40% of respondents in Asia say the...
On World Mental Health Day, NCCN Announces Free Updated Distress Screening Tool, Available in More Than 70 Languages
The National Comprehensive Cancer Network's Distress Thermometer helps people with cancer worldwide receive better care by empowering discussion and recommending best practices for managing psychological wellness. PLYMOUTH MEETING, Pa., Oct. 10, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced an updated NCCN Distress Thermometer, available in more than 70 languages,...
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA)...
The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, is pleased to see that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA)...
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 subjects in 6 dose escalation cohorts and 12 subjects in food effect trial. The enrollment is expected to be completed in the fourth quarter of 2022 --ASC10 is an oral double prodrug. After oral administration, both ASC10 and single prodrug molnupiravir...
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial evaluating XW014, a novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. XW014 is being developed for...
WuXi Biologics Co., Ltd. Removed from Unverified List
WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective October 7, 2022. In February 2022, two subsidiaries of WuXi Biologics,...
AXA BetterMe Weekend concludes on a high note
Brand Ambassador Sammi Cheng motivates the public to become a BetterMe HONG KONG, Oct. 9, 2022 /PRNewswire/ -- To mark World Mental Health Day on 10 October, AXA Hong Kong and Macau ("AXA") brought back the AXA BetterMe Weekend on 8 and 9 October 2022 at AXA x WONDERLAND @West Kowloon Cultural District, to encourage the public to take...
